

Ulf Dahlstrom

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/647735/ulf-dahlstrom-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers

4,491
citations

36
h-index

65
g-index

128
ext. papers

6,015
ext. citations

7.4
avg, IF

5.57
L-index

#	Paper	IF	Citations
119	Regional Differences in Precipitating Factors of Hospitalization for Acute Heart Failure: Insights from the REPORT-HF Registry.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	1
118	Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy.. <i>ESC Heart Failure</i> , 2022 ,	3.7	1
117	A global perspective of racial differences and outcomes in patients presenting with acute heart failure. <i>American Heart Journal</i> , 2022 , 243, 11-14	4.9	2
116	Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure.. <i>ESC Heart Failure</i> , 2022 ,	3.7	1
115	Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	4
114	Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry.. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	2
113	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	9
112	Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021 , 23, 1012-1022	12.3	10
111	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure: REPORT-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 349-359	7.9	1
110	Prognosis and outcome determinants after heart failure diagnosis in patients who underwent aortic valvular intervention. <i>ESC Heart Failure</i> , 2021 , 8, 3237-3247	3.7	2
109	Association Between β Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1165-1174	3.3	1
108	Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 973-982	12.3	11
107	Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003-2015. <i>BMC Cardiovascular Disorders</i> , 2021 , 21, 307	2.3	1
106	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. <i>Heart</i> , 2021 , 107, 229-236	5.1	8
105	Risk of stroke in patients with heart failure and sinus rhythm: data from the Swedish Heart Failure Registry. <i>ESC Heart Failure</i> , 2021 , 8, 85-94	3.7	1
104	Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1051-1062	6.1	5
103	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. <i>Europace</i> , 2021 ,	3.9	1

102	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. <i>International Journal of Cardiology</i> , 2021 , 343, 63-72	3.2	1
101	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021 , 23, 1844-1854	12.3	8
100	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. <i>International Journal of Cardiology</i> , 2020 , 313, 76-82	3.2	9
99	A registry-based algorithm to predict ejection fraction in patients with heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 2388-2397	3.7	4
98	Temporal trends in cause-specific readmissions and their risk factors in heart failure patients in Sweden. <i>International Journal of Cardiology</i> , 2020 , 306, 116-122	3.2	3
97	Young patients with heart failure: clinical characteristics and outcomes. Data from the Swedish Heart Failure, National Patient, Population and Cause of Death Registers. <i>European Journal of Heart Failure</i> , 2020 , 22, 1125-1132	12.3	2
96	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. <i>The Lancet Global Health</i> , 2020 , 8, e411-e422	13.6	46
95	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1390-1398 ¹⁵	12.3	15
94	Higher blood pressure in elderly hypertensive females, with increased arterial stiffness and blood pressure in females with the Fibrillin-1 2/3 genotype. <i>BMC Cardiovascular Disorders</i> , 2020 , 20, 180	2.3	5
93	Evaluation of the usefulness of EQ-5D as a patient-reported outcome measure using the Paretian classification of health change among patients with chronic heart failure. <i>Journal of Patient-Reported Outcomes</i> , 2020 , 4, 50	2.6	3
92	Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 103-112	12.3	15
91	Prognostic impact over time of ischaemic heart disease vs. non-ischaemic heart disease in heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 264-273	3.7	8
90	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 401-410	16.2	20
89	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. <i>American Heart Journal</i> , 2020 , 222, 93-104	4.9	0
88	Iron deficiency in heart failure. <i>International Journal of Cardiology</i> , 2020 , 299, 207	3.2	
87	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 2160-2171	12.3	24
86	Trends in cause-specific readmissions in heart failure with preserved vs. reduced and mid-range ejection fraction. <i>ESC Heart Failure</i> , 2020 , 7, 2894-2903	3.7	3
85	Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. <i>ESC Heart Failure</i> , 2020 , 7, 3633	3.7	6

84	Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum. <i>International Journal of Cardiology</i> , 2020 , 298, 59-65	3.2	18
83	Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 147-155	4.6	1
82	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. <i>Circulation</i> , 2019 , 140, 1530-1539	16.7	41
81	Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019 , 21, 471-479	12.3	26
80	Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications. <i>JACC: Heart Failure</i> , 2019 , 7, 505-515	7.9	50
79	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 306-317	7.9	54
78	Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2019 , 108, 1394-1405	6.1	13
77	N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum. <i>International Journal of Cardiology</i> , 2019 , 287, 66-72	3.2	8
76	Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry. <i>Clinical Research in Cardiology</i> , 2019 , 108, 1025-1033	6.1	36
75	The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. <i>Uppsala Journal of Medical Sciences</i> , 2019 , 124, 65-69	2.8	25
74	Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1661-1662	12.3	2
73	Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the Swedish heart failure register. <i>Scandinavian Journal of Primary Health Care</i> , 2019 , 37, 434-443	2.7	5
72	Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry. <i>ESC Heart Failure</i> , 2019 , 6, 1167-1177	3.7	2
71	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 65-76	7.9	32
70	Clinical and research implications of serum versus plasma potassium measurements. <i>European Journal of Heart Failure</i> , 2019 , 21, 536-537	12.3	9
69	Association of diuretic treatment at hospital discharge in patients with heart failure with all-cause short- and long-term mortality: A propensity score-matched analysis from SwedeHF. <i>International Journal of Cardiology</i> , 2018 , 257, 118-124	3.2	8
68	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 1326-1334	12.3	86
67	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	79

66	Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018 , 254, 203-209	3.2	9
65	Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. <i>Heart</i> , 2018 , 104, 1093-1100	5.1	18
64	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. <i>JACC: Heart Failure</i> , 2018 , 6, 246-256	7.9	22
63	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study. <i>European Journal of Heart Failure</i> , 2018 , 20, 474-480	12.3	15
62	Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2018 , 24, 365-374	3.3	19
61	Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 769-777	12.3	14
60	Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. <i>PLoS Medicine</i> , 2018 , 15, e1002540	11.6	42
59	Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. <i>Diabetes and Vascular Disease Research</i> , 2018 , 15, 494-503	3.3	21
58	New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017 , 19, 366-376	12.3	21
57	The impact of time to heart failure diagnosis on outcomes in patients tailored for heart failure treatment by use of natriuretic peptides. Results from the UPSTEP study. <i>International Journal of Cardiology</i> , 2017 , 236, 315-320	3.2	2
56	Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study. <i>European Journal of Heart Failure</i> , 2017 , 19, 1107-1116	12.3	47
55	Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1270-1279	12.3	54
54	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	104
53	Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2606-2618	15.1	47
52	Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease study and the Cockcroft-Gault equation in patients with heart failure. <i>Open Heart</i> , 2017 , 4, e000568	3	18
51	Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1606-1614	12.3	86
50	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	13
49	Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2017 , 5, 14-24	7.9	42

48	A comprehensive population-based characterization of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1624-1634	12.3	113
47	Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	14
46	Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017 , 5, 565-574	7.9	148
45	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	25
44	Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1404-1416	15.1	53
43	Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 39	2.3	10
42	A comprehensive assessment of the association between anemia, clinical covariates and outcomes in a population-wide heart failure registry. <i>International Journal of Cardiology</i> , 2016 , 211, 124-31	3.2	11
41	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. <i>European Journal of Heart Failure</i> , 2016 , 18, 613-25	12.3	316
40	Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. <i>European Journal of Heart Failure</i> , 2016 , 18, 503-11	12.3	81
39	Prevalence and prognostic impact of kidney disease on heart failure patients. <i>Open Heart</i> , 2016 , 3, e000324	3.2	38
38	Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. <i>Heart</i> , 2016 , 102, 1464-71	5.1	11
37	Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). <i>International Journal of Cardiology</i> , 2016 , 220, 750-8	3.2	8
36	Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of ≥ 50 . <i>Circulation: Heart Failure</i> , 2015 , 8, 862-70	7.6	64
35	Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. <i>Heart</i> , 2015 , 101, 1139-48	5.1	28
34	International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. <i>European Journal of Heart Failure</i> , 2015 , 17, 527-33	12.3	30
33	Responder to BNP-guided treatment in heart failure. The process of defining a responder. <i>Scandinavian Cardiovascular Journal</i> , 2015 , 49, 316-24	2	8
32	Prognostic Significance of Resting Heart Rate and Use of β Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2015 , 8, 871-9	7.6	91
31	Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. <i>Europace</i> , 2015 , 17, 424-31	3.9	39

30	Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. <i>European Journal of Heart Failure</i> , 2015 , 17, 1252-61	12.3	58
29	Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. <i>European Heart Journal</i> , 2015 , 36, 2318-26	9.5	60
28	Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry. <i>Value in Health</i> , 2015 , 18, 439-48	3.3	16
27	Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. <i>European Journal of Heart Failure</i> , 2015 , 17, 612-9	12.3	39
26	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015 , 199, 415-23	3.2	7
25	Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2015 , 8, 252-60	7.6	30
24	Triage of patients with moderate to severe heart failure: who should be referred to a heart failure center?. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 661-671	15.1	28
23	Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. <i>International Journal of Cardiology</i> , 2014 , 175, 55-61	3.2	11
22	Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2014 , 16, 409-18	12.3	33
21	Resource use and cost implications of implementing a heart failure program for patients with systolic heart failure in Swedish primary health care. <i>International Journal of Cardiology</i> , 2014 , 176, 731-8 ^{3,2}	3.2	8
20	Proinsulin and IGFBP-1 predicts mortality in an elderly population. <i>International Journal of Cardiology</i> , 2014 , 174, 260-7	3.2	4
19	Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. <i>European Heart Journal</i> , 2014 , 35, 1559-67	9.5	176
18	Association between use of Eblockers and outcomes in patients with heart failure and preserved ejection fraction. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 2008-18	27.4	106
17	Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study. <i>Circulation: Heart Failure</i> , 2013 , 6, 174-83	7.6	27
16	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013 , 15, 1173-84	12.3	388
15	EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2013 , 15, 808-17	12.3	462
14	Association of candesartan vs losartan with all-cause mortality in patients with heart failure. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 175-82	27.4	46
13	EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010 , 12, 1076-84	12.3	258

12	Heart failure registry: a valuable tool for improving the management of patients with heart failure. <i>European Journal of Heart Failure</i> , 2010 , 12, 25-31	12.3	111
11	B-Type Natriuretic Peptide: Application in the Community. <i>Congestive Heart Failure</i> , 2008 , 14, 12-16		2
10	Integration of B-Type Natriuretic Peptide in Heart Failure Outpatient Programs. <i>Congestive Heart Failure</i> , 2008 , 14, 9-11		
9	Integration of B-type natriuretic Peptide in heart failure outpatient programs. <i>Congestive Heart Failure</i> , 2008 , 14, 9-11		1
8	Frequent non-cardiac comorbidities in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2005 , 7, 309-16	12.3	71
7	1410 Depression and Patients with Chronic Heart Failure. A Review of the Literature. <i>European Journal of Cardiovascular Nursing</i> , 2005 , 4, 48-49	3.3	
6	Nurse-led heart failure clinics in Sweden. <i>European Journal of Heart Failure</i> , 2001 , 3, 139-44	12.3	63
5	Patients with congestive heart failure and their conceptions of their sleep situation. <i>Journal of Advanced Nursing</i> , 2001 , 34, 520-9	3.1	47
4	Prenalterol as long-term therapy for chronic congestive heart failure. A randomized cross-over trial. <i>Acta Medica Scandinavica</i> , 1984 , 216, 199-207		13
3	Hemodynamics and leg muscle metabolism at rest and during exercise in young healthy men after prenalterol. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 701-9	6.1	5
2	Prenalterol in the treatment of congestive heart failure developing during beta-blocking therapy. A comparison with frusemide in patients with acute myocardial infarction. <i>Acta Medica Scandinavica</i> , 1982 , 212, 125-30		2
1	Established beta-adrenergic receptor blocking therapy and acute myocardial infarction. A clinical study of risks and benefits. <i>Acta Medica Scandinavica</i> , 1980 , 207, 167-71		3